Advertisement

Inflammopharmacology

, Volume 22, Issue 2, pp 79–94 | Cite as

Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

  • Stephen D. Skaper
  • Laura Facci
  • Mariella Fusco
  • Maria Federica della Valle
  • Morena Zusso
  • Barbara Costa
  • Pietro Giusti
Review

Abstract

Persistent pain affects nearly half of all people seeking medical care in the US alone, and accounts for at least $80 billion worth of lost productivity each year. Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage or disease of the somatosensory nervous system, and remains largely untreatable. With few available treatment options, neuropathic pain represents an area of significant and growing unmet medical need. Current treatment of peripheral neuropathic pain involves several drug classes, including opioids, gabapentinoids, antidepressants, antiepileptic drugs, local anesthetics and capsaicin. Even so, less than half of patients achieve partial relief. This review discusses a novel approach to neuropathic pain management, based on knowledge of: the role of glia and mast cells in pain and neuroinflammation; the body’s innate mechanisms to maintain cellular homeostasis when faced with external stressors provoking, for example, inflammation. The discovery that palmitoylethanolamide, a member of the N-acylethanolamine family which is produced from the lipid bilayer on-demand, is capable of exerting anti-allodynic and anti-hyperalgesic effects by down-modulating both microglial and mast cell activity has led to the application of this fatty acid amide in several clinical studies of neuropathic pain, with beneficial outcome and no indication of adverse effects at pharmacological doses. Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain.

Keywords

Neuropathic pain Mast cells Microglia Neuro-immune interaction Natural products Palmitoylethanolamide 

Notes

Acknowledgments

The authors wish to thank Gabriele Marcolongo for his valuable input in providing details of the micronization/ultra-micronization process for PEA, and the associated figures and data. L. Facci was supported by Fondazione CARIPARO “Progetto Dottorati di Ricerca” Anno 2009. This study was supported in part by MIUR, PON ‘Ricerca e Competitività 2007–2013’ project PON01_02512.

Conflict of interest

MF is an employee of Epitech Srl; MFdV is a scientific consultant for Innovet Italia Srl.

References

  1. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108:1687–1707PubMedCentralPubMedGoogle Scholar
  2. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M (2013) Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168:1430–1444PubMedCentralPubMedGoogle Scholar
  3. Assini A, Laricchia D, Belletti M, Pandolfini L, Pizzo R, Ratto S (2010) The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide. EFNS Eur J Neurol 17(Suppl. 3):141–145Google Scholar
  4. Bacci C, Cassetta G, Emanuele B, Berengo M (2011) Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg 2011:917350PubMedCentralPubMedGoogle Scholar
  5. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B (2013) Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 12:34–44PubMedGoogle Scholar
  6. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272:3315–3323PubMedGoogle Scholar
  7. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP (2013) The resolution of inflammation. Nat Rev Immunol 13:59–66PubMedGoogle Scholar
  8. Bulanova E, Bulfone-Paus S (2010) P2 receptor-mediated signaling in mast cell biology. Purinergic Signal 6:3–17PubMedCentralPubMedGoogle Scholar
  9. Calabrò RS, Bramanti P (2013) Occipital neuralgia responding to palmitoylethanolamide. Headache. doi: 10.1111/head.12136
  10. Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P (2010) Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 11:781–784PubMedGoogle Scholar
  11. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277–281PubMedGoogle Scholar
  12. Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191–198PubMedGoogle Scholar
  13. Calvo M, Dawes JM, Bennett DL (2012) The role of the immune system in the generation of neuropathic pain. Lancet Neurol 11:629–642PubMedGoogle Scholar
  14. Canteri L, Petrosino S, Guida G (2010) Riduzione del consumo di antinfiammatori e analgesici nella terapia del dolore neuropático cronico in pazienti affetti da lombosciatalgia di tipo compressivo e in trattamento con NORMAST® 300 mg. Dolor 25:227–234Google Scholar
  15. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A (2010) Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Vet Immunol Immunopathol 133:9–15PubMedGoogle Scholar
  16. Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, Colacurci N (2011) Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 158:82–86PubMedGoogle Scholar
  17. Coburn AF, Moore LV (1943) Nutrition as conditioning factor in the rheumatic state. Am J Dis Child 65:744–756Google Scholar
  18. Coburn AF, Graham CE, Hahinger J (1954) Effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J Exp Med 100:425–435PubMedCentralPubMedGoogle Scholar
  19. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V (2011) Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med 102:141–147PubMedGoogle Scholar
  20. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G (2002) Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135:181–187PubMedCentralPubMedGoogle Scholar
  21. Costa B, Conti S, Giagnoni G, Colleoni M (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmcol 137:413–420Google Scholar
  22. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G (2008) The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139:541–550PubMedGoogle Scholar
  23. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83–87PubMedGoogle Scholar
  24. Crestani F, Burato A, Tartari S (2013) Aumento dell’analgesia da agopuntura nel dolore da radicolopatia con il composto cannabimimetico Palmitoiletanolamide: studio pilota. Giornale Italiano di Medicina Riabilitativa 7:1Google Scholar
  25. Cunningham C (2013) Microglia and neurodegeneration: the role of systemic inflammation. Glia 61:71–90PubMedGoogle Scholar
  26. D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Raso GM, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A (2007) Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-α agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322:1137–1143PubMedGoogle Scholar
  27. D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A (2009) Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 613:54–59PubMedGoogle Scholar
  28. de Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T (2011) Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 10:3. doi: 10.1186/1744-8069-7-3 Google Scholar
  29. de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, Marabese I, D’Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S (2012) Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 676:41–50PubMedGoogle Scholar
  30. De Petrocellis L, Davis JB, Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506:253–256PubMedGoogle Scholar
  31. Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO (2013) Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One 8:e60529PubMedCentralPubMedGoogle Scholar
  32. Desio P (2010) Associazione tra pregabalin e palmitoiletanolamide per il trattamento del dolore neuropático. Pathos 7:9–14Google Scholar
  33. Desio P (2011) Associazione dell’ossicodone a lenta titolazione con Palmitoiletanolamide per il trattamento del low back pain Anestesia e Medicina critica (AMC) 1:63-71Google Scholar
  34. Desio P, Bonadiman L, Fusco M, Cenacchi T (2010) Combination of carbamazepine and palmitoylethanolamide for trigminal neuralgia. PeriMed 4:4Google Scholar
  35. Di Cesare Mannelli L, D’Agostino G, Pacini A, Russo R, Zanardelli M (2013) Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013:328797. doi: 10.1155/2013/328797 PubMedCentralPubMedGoogle Scholar
  36. Dirckx M, Groeneweg G, van Daele PL, Stronks DL, Huygen FJ (2013) Mast cells: a new target in the treatment of complex regional pain syndrome? Pain Pract. doi: 10.1111/papr.12049 Google Scholar
  37. Domínguez CM, Martín AD, Ferrer FG, Ibáñez Puertas MA, Muro AL, Martí González JC, Prieto JP, Taberna IR (2012) N-palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manage 2:119–124Google Scholar
  38. Dworkin RH (2012) Mechanism-based treatment of pain. Pain 153:2300PubMedGoogle Scholar
  39. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3 Suppl):S3–S14PubMedCentralPubMedGoogle Scholar
  40. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376–3380PubMedCentralPubMedGoogle Scholar
  41. Farquhar-Smith WP, Rice AS (2001) Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94:507–513 discussion 6APubMedGoogle Scholar
  42. Farquhar-Smith WP, Rice AS (2003) A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99:1391–1401PubMedGoogle Scholar
  43. Farquhar-Smith WP, Jaggar SI, Rice AS (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97:11–21PubMedGoogle Scholar
  44. Forsythe P, Bienenstock J (2012) The mast cell-nerve functional unit: a key component of physiologic and pathophysiologic responses. Chem Immunol Allergy 98:196–221PubMedGoogle Scholar
  45. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003) Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767–7775PubMedGoogle Scholar
  46. Fulghesu A, Magnini R, Mazzella S, Cappai A, Orrù A, Pisu M. (2010) Treatment of adolescent dysmenorrehea by a new inhibitor of mast cells-induced inflammation (palmitoiletanolamide + trans polidatina) 16° Congresso Pediatric and Adolescent Gynecology—Montpellier (France), 22–25 maggio 2010Google Scholar
  47. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF (2012) Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 13:1121–1130PubMedGoogle Scholar
  48. George AK, Sadek MA, Saluja SS, Fariello JY, Whitmore KE, Moldwin RM (2012) The impact of neuropathic pain in the chronic pelvic pain population. J Urol 188:1783–1787PubMedGoogle Scholar
  49. Ghafouri N, Ghafouri B, Larsson B, Turkina MV, Karlsson L, Fowler CJ, Gerdle B (2011) High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One 6:e27257. doi: 10.1371/journal.pone.0027257 PubMedCentralPubMedGoogle Scholar
  50. Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B (2013) Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain. doi: 10.1016/j.pain.2013.05.002 PubMedGoogle Scholar
  51. Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R (2013) The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol 168:209–213PubMedGoogle Scholar
  52. Gosselin RD, Suter MR, Ji RR, Decosterd I (2010) Glial cells and chronic pain. Neuroscientist 16:519–531PubMedCentralPubMedGoogle Scholar
  53. Guida G, de Fabiani A, Lanaia F, Cantieri L, Alexandre A, Vassallo GM, Rogai M, Lanaia F, Petrosino S (2010) La palmitoiletanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolor 25:35–42Google Scholar
  54. Haller VL, Cichewicz DL, Welch SP (2006) Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546:60–68PubMedGoogle Scholar
  55. Hansen HS, Diep TA (2009) N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 78:553–560PubMedGoogle Scholar
  56. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J (2003) Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73:2345–2353PubMedGoogle Scholar
  57. Indraccolo U, Barbieri F (2010) Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 150:76–79PubMedGoogle Scholar
  58. Jack DB (1996) Aliamides: a new approach to the treatment of inflammation. Drug News Perspect 9:93–98Google Scholar
  59. Jaggar SI, Hasnie FS, Sellaturay S, Rice SA (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76:189–199PubMedGoogle Scholar
  60. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, Treede RD (2011) A new definition of neuropathic pain. Pain 152:2204–2205PubMedGoogle Scholar
  61. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V (2008) Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55:85–93PubMedGoogle Scholar
  62. Kerstman E, Ahn S, Battu S, Tariq S, Grabois M (2013) Neuropathic pain. Handb Clin Neurol 110:175–187PubMedGoogle Scholar
  63. Khasabova IA, Xiong Y, Coicou LG, Piomelli D, Seybold V (2012) Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci 32:12735–12743PubMedCentralPubMedGoogle Scholar
  64. Kopsky DJ, Hesselink JM (2012) Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med 30:53–55PubMedGoogle Scholar
  65. Kuehl FA Jr, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP (1957) The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc 79:5577–5578Google Scholar
  66. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42:321–327PubMedGoogle Scholar
  67. Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D (2013) The burden associated with neuropathic pain in Western Europe. J Med Econ 16:85–95PubMedGoogle Scholar
  68. Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720–4726PubMedCentralPubMedGoogle Scholar
  69. Levy D, Kainz V, Burstein R, Strassman AM (2012) Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun 26:311–317PubMedCentralPubMedGoogle Scholar
  70. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005a) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19PubMedGoogle Scholar
  71. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D (2005b) The search for the palmitoylethanolamide receptor. Life Sci 77:1685–9168Google Scholar
  72. Lo Verme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319:1051–1061Google Scholar
  73. Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F (2008) Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28:633–641PubMedGoogle Scholar
  74. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 12:45–54PubMedGoogle Scholar
  75. Maione S, Costa B, Di Marzo V (2013) Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. pii: S0304-3959(13)00118-8Google Scholar
  76. Mao J, Gold MS, Backonja MM (2011) Combination drug therapy for chronic pain: a call for more clinical studies. J Pain 12:157–166PubMedCentralPubMedGoogle Scholar
  77. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA (2012) Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain 26:99–104PubMedGoogle Scholar
  78. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon L (1996) N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur J Pharmacol 300:227–236PubMedGoogle Scholar
  79. McDougall JJ, Linton P (2012) Neurophysiology of arthritis pain. Curr Pain Headache Rep 16:485–491PubMedGoogle Scholar
  80. Milligan ED, Watkins LR (2009) Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10:23–36PubMedCentralPubMedGoogle Scholar
  81. Mizisin AP, Weerasuriya A (2011) Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol 121:291–312PubMedCentralPubMedGoogle Scholar
  82. Moalem G, Tracey DJ (2006) Immune and inflammatory mechanisms in neuropathic pain. Brain Res Brain Res Rev 51:240–264Google Scholar
  83. Muccioli GG, Stella N (2008) Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 54:16–22PubMedCentralPubMedGoogle Scholar
  84. Murina F, Graziottin A, Felice R, Radici G, Tognocchi C (2013) Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis 17:111–116PubMedGoogle Scholar
  85. Naderi N, Majidi M, Mousavi Z, Khoramian Tusi S, Mansouri Z, Khodagholi F (2012) The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats. Neurochem Res 37:778–785PubMedGoogle Scholar
  86. Nicotra L, Loram LC, Watkins LR, Hutchinson MR (2012) Toll-like receptors in chronic pain. Exp Neurol 234:316–329PubMedCentralPubMedGoogle Scholar
  87. Nightingale S (2012) The neuropathic pain market. Nat Rev Drug Discov 11:101–102PubMedGoogle Scholar
  88. O’Connor AB (2009) Neuropathic pain: a review of the quality of life impact, costs, and cost-effectiveness of therapy. Pharmacoeconomics 27:95–112PubMedGoogle Scholar
  89. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298–5305PubMedGoogle Scholar
  90. Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462PubMedCentralPubMedGoogle Scholar
  91. Parabita M, D’Amore RM, Marinosci F, Matera MG, Izzo A, Russo GA (2011) Reduction of post stroke spasticity with Palmitoylethanolamide treatment. XIV Congress of the European Shock Society. Taormina, August 31, September 2 2011Google Scholar
  92. Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S (2013) Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflamm. doi: 10.1186/1742-2094-10-20 Google Scholar
  93. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415–422PubMedGoogle Scholar
  94. Petrosino S, Iuvone T, Di Marzo V (2010) N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 92:724–727PubMedGoogle Scholar
  95. Rao S, Song Y, Peddie F, Evans AM (2011) Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs. Int J Nanomed 6:1245–1251Google Scholar
  96. Raso GM, Esposito E, Vitiello S, Iacono A, Santoro A, D’Agostino G, Sasso O, Russo R, Piazza PV, Calignano A, Meli R (2011) Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α. J Neuroendocrinol 23:591–600PubMedGoogle Scholar
  97. Ren K, Dubner R (2010) Interactions between the immune and nervous systems in pain. Nat Med 16:1267–1276PubMedCentralPubMedGoogle Scholar
  98. Romano MR, Lograno MD (2012) Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery. Eur J Pharmacol 683:197–203PubMedGoogle Scholar
  99. Romero TR, Galdino GS, Silva GC, Resende LC, Perez AC, Cortes SF, Duarte ID (2012) Involvement of the l-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. J Neurosci Res 90:1474–1479PubMedGoogle Scholar
  100. Romero TR, Pacheco Dda F, Duarte ID (2013a) Probable involvement of Ca2+-activated Cl channels (CaCCs) in the activation of CB1 cannabinoid receptors. Life Sci 116:815–820Google Scholar
  101. Romero TR, Resende LC, Guzzo LS, Duarte ID (2013b) CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 116:463–472PubMedGoogle Scholar
  102. Sacerdote P, Franchi S, Moretti S, Castelli M, Procacci P, Magnaghi V, Panerai AE (2013) Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. J Neuroimmune Pharmacol 8:202–211PubMedGoogle Scholar
  103. Sareen S, Mathew G, Joseph L (2012) Improvement in solubility of poor water-soluble drugs by solid dispersion. Int J Pharm Investig 2:12–17PubMedCentralPubMedGoogle Scholar
  104. Sasso O, Russo R, Vitiello S, Raso GM, D’Agostino G, Iacono A, Rana GL, Vallée M, Cuzzocrea S, Piazza PV, Meli R, Calignano A (2012) Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain 153:33–41PubMedGoogle Scholar
  105. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C (2013) Palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Panminerva Med (in press)Google Scholar
  106. Schmid PC, Reddy PV, Natarajan V, Schmid HH (1983) Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem 258:9302–9306PubMedGoogle Scholar
  107. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197PubMedGoogle Scholar
  108. Skaper SD (2013) Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. CNS Neurol Disord Drug Targets 12:4–6PubMedGoogle Scholar
  109. Skaper SD, Facci L (2012) Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 367:3312–3325PubMedCentralPubMedGoogle Scholar
  110. Skaper SD, Giusti P, Facci L (2012) Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 26:3103–3117PubMedGoogle Scholar
  111. Smith BH, Torrance N (2012) Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 16:191–198PubMedGoogle Scholar
  112. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D (2009) Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci USA 106:20966–20971PubMedCentralPubMedGoogle Scholar
  113. Sung B, Lim G, Mao J (2003) Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 23:2899–2910PubMedGoogle Scholar
  114. Tabas I, Glass CK (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166–172PubMedCentralPubMedGoogle Scholar
  115. Tawfik VL, Lacroix-Fralish ML, Bercury KK, Nutile-McMenemy N, Harris BT, Deleo JA (2006) Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. Glia 54:193–203PubMedGoogle Scholar
  116. Tore F, Tuncel N (2009) Mast cells: target and source of neuropeptides. Curr Pharm Des 15:3433–3445PubMedGoogle Scholar
  117. Toth C, Lander J, Wiebe S (2009) The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 10:918–929PubMedGoogle Scholar
  118. Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci MT, Cruccu G (2011) Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets 10:916–920PubMedGoogle Scholar
  119. Tsai M, Grimbaldeston M, Galli SJ (2011) Mast cells and immunoregulation/immunomodulation. Adv Exp Med Biol 716:186–211PubMedGoogle Scholar
  120. Tsuboi K, Takezaki N, Ueda N (2007) The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4:1914–1925PubMedGoogle Scholar
  121. Tsuboi K, Ikematsu N, Uyama T, Deutsch DG, Tokumura A, Ueda N (2013) Biosynthetic pathways of bioactive N-acylethanolamines in brain. CNS Neurol Disord Drug Targets 12:7–16PubMedGoogle Scholar
  122. Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K (2013) Microglial regulation of neuropathic pain. J Pharmacol Sci 121:89–94PubMedGoogle Scholar
  123. Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS Lett 280:1874–1894Google Scholar
  124. Varrassi G, Collett B, Morlion B, Kalso E, Nicolaou A, Dickenson A, Pergolizzi J, Schäfer M, Müller-Schwefe G (2011) Proceedings of the CHANGE PAIN Expert Summit in Rome, June 2010. Curr Med Res Opin 27:2061–2062PubMedGoogle Scholar
  125. Wilkerson JL, Milligan ED (2011) The central role of glia in pathological pain and the potential of targeting the cannabinoid 2 receptor for pain relief. ISRN Anesthesiol. doi: 10.5402/2011/593894 PubMedCentralPubMedGoogle Scholar
  126. Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T (2005) Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int Arch Allergy Immunol 138:80–87PubMedGoogle Scholar
  127. Yuan H, Zhu X, Zhou S, Chen Q, Zhu X, Ma X, He X, Tian M, Shi X (2010) Role of mast cell activation in inducing microglial cells to release neurotrophin. J Neurosci Res 88:1348–1354PubMedGoogle Scholar
  128. Zhang S, Zeng X, Yang H, Hu G, He S (2012) Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. Cell Physiol Biochem 29:931–940PubMedGoogle Scholar
  129. Zhu C, Solorzano C, Sahar S, Realini N, Fung E, Sassone-Corsi P, Piomelli D (2011) Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol 79:786–792PubMedCentralPubMedGoogle Scholar
  130. Zuo Y, Perkins NM, Tracey DJ, Geczy CL (2003) Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain 105:467–479PubMedGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Stephen D. Skaper
    • 1
  • Laura Facci
    • 1
  • Mariella Fusco
    • 2
  • Maria Federica della Valle
    • 3
  • Morena Zusso
    • 1
  • Barbara Costa
    • 4
  • Pietro Giusti
    • 1
  1. 1.Department of Pharmaceutical and Pharmacological SciencesUniversity of PaduaPaduaItaly
  2. 2.Epitech Group Srl, Scientific Information and Documentation CenterSaccolongoItaly
  3. 3.CeDIS (Scientific Information and Documentation Center), Innovet Italia SrlSaccolongoItaly
  4. 4.Department of Biotechnology and Bioscience, University of Milan-BicoccaMilanItaly

Personalised recommendations